• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tiziana Life Sciences Ltd - Common Shares (NQ:TLSA)

1.370 -0.080 (-5.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 96,757
Open 1.410
Bid (Size) 1.330 (600)
Ask (Size) 1.370 (100)
Prev. Close 1.450
Today's Range 1.370 - 1.420
52wk Range 1.140 - 2.600
Shares Outstanding 194,612,289
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab
May 14, 2026
Foralumab is the first intranasal immune modulator in clinical trials for patients with Multiple System Atrophy 
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function
April 16, 2026
Data from independent academic collaborators published on bioRxiv support the therapeutic potential of the Company’s lead candidate, intranasal foralumab, for Long COVID associated “brain fog”. 
From Tiziana Life Sciences Ltd.
Via GlobeNewswire

Performance

YTD
-14.4%
-14.4%
1 Month
+6.2%
+6.2%
3 Month
+3.0%
+3.0%
6 Month
-17.0%
-17.0%
1 Year
-5.5%
-5.5%

More News

Read More
News headline image
Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress
April 14, 2026
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Stock Rises On Advancing Second Asset Besides Foralumab: Retail Thinks Stock Has ‘So Much Potential’ ↗
September 25, 2025
Via Stocktwits
News headline image
Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging
April 01, 2026
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA
February 25, 2026
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab
January 20, 2026
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares
January 16, 2026
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million
January 16, 2026
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco
January 09, 2026
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA
December 29, 2025
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman
December 19, 2025
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences to Ring the Closing Bell at Nasdaq
December 17, 2025
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical Trial
December 17, 2025
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
December 15, 2025
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering
December 15, 2025
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer’s Trial
December 12, 2025
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company
December 02, 2025
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program
November 25, 2025
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference
November 13, 2025
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Elon Musk Says Tesla, xAI Are 'Trending Towards Convergence' In Some Ways ↗
November 10, 2025
Via Benzinga
Topics Artificial Intelligence
News headline image
Aquestive Therapeutics Announces Leadership Expansion to Support Growth
November 04, 2025
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy
October 29, 2025
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia
September 30, 2025
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody
September 25, 2025
From Tiziana Life Sciences Ltd.
Via GlobeNewswire

Frequently Asked Questions

Is Tiziana Life Sciences Ltd - Common Shares publicly traded?
Yes, Tiziana Life Sciences Ltd - Common Shares is publicly traded.
What exchange does Tiziana Life Sciences Ltd - Common Shares trade on?
Tiziana Life Sciences Ltd - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Tiziana Life Sciences Ltd - Common Shares?
The ticker symbol for Tiziana Life Sciences Ltd - Common Shares is TLSA on the Nasdaq Stock Market
What is the current price of Tiziana Life Sciences Ltd - Common Shares?
The current price of Tiziana Life Sciences Ltd - Common Shares is 1.370
When was Tiziana Life Sciences Ltd - Common Shares last traded?
The last trade of Tiziana Life Sciences Ltd - Common Shares was at 05/15/26 04:00 PM ET
What is the market capitalization of Tiziana Life Sciences Ltd - Common Shares?
The market capitalization of Tiziana Life Sciences Ltd - Common Shares is 266.62M
How many shares of Tiziana Life Sciences Ltd - Common Shares are outstanding?
Tiziana Life Sciences Ltd - Common Shares has 267M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap